SG11201408419QA - Method for preparing substituted triazolopyridines - Google Patents

Method for preparing substituted triazolopyridines

Info

Publication number
SG11201408419QA
SG11201408419QA SG11201408419QA SG11201408419QA SG11201408419QA SG 11201408419Q A SG11201408419Q A SG 11201408419QA SG 11201408419Q A SG11201408419Q A SG 11201408419QA SG 11201408419Q A SG11201408419Q A SG 11201408419QA SG 11201408419Q A SG11201408419Q A SG 11201408419QA
Authority
SG
Singapore
Prior art keywords
international
str
preparing substituted
monheim
english
Prior art date
Application number
SG11201408419QA
Other languages
English (en)
Inventor
Volker Schulze
Franz-Josef Mais
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SG11201408419QA publication Critical patent/SG11201408419QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201408419QA 2012-07-10 2013-07-03 Method for preparing substituted triazolopyridines SG11201408419QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12175640 2012-07-10
EP12185590 2012-09-24
EP13170585 2013-06-05
PCT/EP2013/064017 WO2014009219A1 (en) 2012-07-10 2013-07-03 Method for preparing substituted triazolopyridines

Publications (1)

Publication Number Publication Date
SG11201408419QA true SG11201408419QA (en) 2015-01-29

Family

ID=48793197

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408419QA SG11201408419QA (en) 2012-07-10 2013-07-03 Method for preparing substituted triazolopyridines

Country Status (24)

Country Link
US (1) US9388177B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2872506A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6238979B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20150040845A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104603136B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP3778A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013289381A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112015000308A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2878481A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2015000038A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO7160002A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (1) CR20150006A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DO (1) DOP2015000007A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA027544B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1206731A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL236265A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2015DN00085A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2015000348A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ703020A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20150354A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH12015500061A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201408419QA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TN (1) TN2015000008A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2014009219A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2914521A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines having activity as mps-1 inhibitors
KR20160018534A (ko) 2013-06-11 2016-02-17 바이엘 파마 악티엔게젤샤프트 Mps-1 키나제 억제제 및 유사분열 억제제를 포함하는 암의 치료를 위한 조합물
EA201600002A1 (ru) * 2013-06-11 2016-06-30 Байер Фарма Акциенгезельшафт Производные пролекарства замещенных триазолопиридинов
FI3283642T3 (fi) 2015-04-17 2024-01-11 Crossfire Oncology Holding B V Prognostisia biomarkkereita ttk-inhibiittorikemoterapiaan
TW201800408A (zh) 2016-06-15 2018-01-01 拜耳製藥公司 Mps-1抑制劑

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003030937A1 (ja) * 2001-10-05 2005-01-20 小野薬品工業株式会社 ミトコンドリアルベンゾジアゼピン受容体アンタゴニストからなるストレス疾患の治療剤
JP2007537296A (ja) * 2004-05-14 2007-12-20 アボット・ラボラトリーズ 治療薬としてのキナーゼ阻害薬
UA89503C2 (uk) * 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
EP1799680A2 (en) * 2004-10-07 2007-06-27 Warner-Lambert Company LLC Triazolopyridine derivatives as antibacterial agents
US20060194823A1 (en) * 2004-12-22 2006-08-31 Georg Kettschau Sulfonamido-macrocycles as Tie2 inhibitors and the salts thereof, a pharmaceutical composition comprising these compounds, the method of preparing and the use thereof
CN101516883A (zh) * 2006-06-06 2009-08-26 先灵公司 作为蛋白激酶抑制剂的咪唑并吡嗪化合物
EP1870416A1 (en) * 2006-06-21 2007-12-26 Bayer Schering Pharma Aktiengesellschaft Sulphonamido-macrocycles as tie2 inhibitors
SG174086A1 (en) 2006-08-30 2011-09-29 Cellzome Ltd Triazole derivatives as kinase inhibitors
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
AU2008277628B2 (en) 2007-07-18 2012-03-15 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
AU2008290330A1 (en) 2007-08-23 2009-02-26 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of TTK/Mps1 for the treatment of proliferative disorders
JP2010536917A (ja) 2007-08-31 2010-12-02 メルク セローノ ソシエテ アノニム トリアゾロピリジン化合物と、ａｓｋ阻害剤としてのその化合物の利用法
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB0724342D0 (en) * 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
WO2009137322A2 (en) * 2008-05-05 2009-11-12 The Trustees Of The University Of Pennsylvania Processes for the preparation of biphenyl compounds
US20110212053A1 (en) * 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors
BRPI1008850A2 (pt) 2009-02-13 2016-03-15 Fovea Pharmaceuticals [1,2,4]triazolo[1,5-a]piridinas como inibidores de quinase
ES2547328T3 (es) 2009-04-29 2015-10-05 Bayer Intellectual Property Gmbh Imidazoquinoxalinas sustituidas
WO2010141360A1 (en) * 2009-06-05 2010-12-09 Merck Sharp & Dohme Corp. Biaryl benzotriazole derivatives
MX2011012961A (es) * 2009-06-05 2012-01-30 Cephalon Inc Preparacion y usos de derivados de 1,2,4-triazolo[1,5a]-piridina.
WO2011026579A1 (en) 2009-09-04 2011-03-10 Bayer Schering Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
WO2012044567A2 (en) * 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Imidazole derivatives
PE20141351A1 (es) * 2011-04-21 2014-11-01 Bayer Ip Gmbh Triazolopiridinas
WO2012160029A1 (en) * 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk

Also Published As

Publication number Publication date
PH12015500061A1 (en) 2015-03-02
JP6238979B2 (ja) 2017-11-29
BR112015000308A2 (pt) 2017-06-27
TN2015000008A1 (en) 2016-06-29
JP2015523372A (ja) 2015-08-13
CR20150006A (es) 2015-02-16
MX2015000348A (es) 2015-04-14
KR20150040845A (ko) 2015-04-15
US9388177B2 (en) 2016-07-12
EA201590116A1 (ru) 2015-07-30
AP2014008177A0 (en) 2014-12-31
IL236265A (en) 2017-07-31
NZ703020A (en) 2017-08-25
DOP2015000007A (es) 2015-02-15
CN104603136A (zh) 2015-05-06
WO2014009219A1 (en) 2014-01-16
EP2872506A1 (en) 2015-05-20
IN2015DN00085A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-05-29
AP3778A (en) 2016-08-31
PE20150354A1 (es) 2015-03-21
CA2878481A1 (en) 2014-01-16
AU2013289381A1 (en) 2015-01-22
US20150148542A1 (en) 2015-05-28
IL236265A0 (en) 2015-02-26
CO7160002A2 (es) 2015-01-15
EA027544B1 (ru) 2017-08-31
HK1206731A1 (en) 2016-01-15
CL2015000038A1 (es) 2015-03-13
CN104603136B (zh) 2017-06-27

Similar Documents

Publication Publication Date Title
SG11201906763RA (en) Pyrrolo [1,2-b] pyridazine derivatives
SG11201408261UA (en) Syringe
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201408094YA (en) Neprilysin inhibitors
SG11201408641UA (en) Phenoxyethyl piperidine compounds
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201407200TA (en) Liquid formulation
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201908640TA (en) Pyrrolidinones and a process to prepare them
SG11201408237YA (en) Compound as wnt signaling inhibitor, composition, and use thereof
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201407037UA (en) Catechol o-methyltransferase activity inhibiting compounds
SG11201407596TA (en) Conjugation reagents
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201407536UA (en) Topical pharmaceutical compositions comprising terbinafine and urea
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201402986RA (en) Kinase inhibitors
SG11201407345QA (en) Pyrazole compounds as sglt1 inhibitors
SG11201408502XA (en) Method of purifying an antibody
SG11201408419QA (en) Method for preparing substituted triazolopyridines
SG11201407599SA (en) Oligonucleotide chelate complex-polypeptide compositions and methods
SG11201807773QA (en) Malassezin and analogs thereof as skin brightening agents
SG11201406745VA (en) Methods of therapeutic monitoring of phenylacetic acid prodrugs